HC
VRTX icon

Henshaw Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Henshaw Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,066
Closed -$252K – 381
2020
Q4 		$252K Buy
+1,066
New +$245K 0.02% 290

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Henshaw Capital's VRTX Position: Q1 2021 in Review

Henshaw Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 1,066 shares — an estimated $252K sold.

Henshaw Capital first reported a position in VRTX in Q4 2020 and held it in 1 quarter. The position peaked at $252K in Q4 2020. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • Henshaw Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Henshaw Capital sold 1,066 Vertex Pharmaceuticals shares in Q1 2021, an estimated $252K.
  • Henshaw Capital first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Henshaw Capital's Vertex Pharmaceuticals position peaked at $252K in Q4 2020.
  • 999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Henshaw Capital's 13F filing for Q1 2021, filed 28 May 2026.